Literature DB >> 14962584

Impact of solid state properties on developability assessment of drug candidates.

Lian-Feng Huang1, Wei-Qin Tong.   

Abstract

Solid state properties including polymorphism, solvate and salt formation can have a profound impact on two of the most important properties that are essential to the successful development of drug candidates: solubility and stability. To enable meaningful evaluations of drug candidates for their development risks, often referred to as developability, and provide input to the molecular design regarding the "drug-like" properties, one must take into account the impact of solid state properties on solubility and stability. This review examines the importance of solid state properties and their relationship to developability criteria. Phase appropriate characterization strategies and appropriate salt and crystal form screening and selection processes are discussed. These strategies and processes should balance the need for speed and throughput of modern discovery with the quality of data essential to the adequate developability assessment. Specific examples are given to illustrate the importance of understanding the solid state properties and their impact on developability.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962584     DOI: 10.1016/j.addr.2003.10.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  28 in total

1.  Release profile and characteristics of electrosprayed particles for oral delivery of a practically insoluble drug.

Authors:  Adam Bohr; Jakob Kristensen; Mark Dyas; Mohan Edirisinghe; Eleanor Stride
Journal:  J R Soc Interface       Date:  2012-04-25       Impact factor: 4.118

2.  Discovery pharmaceutics--challenges and opportunities.

Authors:  Xue-Qing Chen; Melissa D Antman; Christoph Gesenberg; Olafur S Gudmundsson
Journal:  AAPS J       Date:  2006-06-02       Impact factor: 4.009

Review 3.  Recent progress in the computational prediction of aqueous solubility and absorption.

Authors:  Stephen R Johnson; Weifan Zheng
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

4.  Crystal morphology engineering of pharmaceutical solids: tabletting performance enhancement.

Authors:  Sabiruddin Mirza; Inna Miroshnyk; Jyrki Heinämäki; Osmo Antikainen; Jukka Rantanen; Pia Vuorela; Heikki Vuorela; Jouko Yliruusi
Journal:  AAPS PharmSciTech       Date:  2009-01-30       Impact factor: 3.246

5.  A novel three-dimensional large-pore mesoporous carbon matrix as a potential nanovehicle for the fast release of the poorly water-soluble drug, celecoxib.

Authors:  Yanzhuo Zhang; Hong Wang; Chuanjun Li; Baoxiang Sun; Yu Wang; Siling Wang; Cunqiang Gao
Journal:  Pharm Res       Date:  2013-11-28       Impact factor: 4.200

6.  Probing the effects of experimental conditions on the character of drug-polymer phase diagrams constructed using Flory-Huggins theory.

Authors:  Conor Donnelly; Yiwei Tian; Catherine Potter; David S Jones; Gavin P Andrews
Journal:  Pharm Res       Date:  2014-07-30       Impact factor: 4.200

Review 7.  Preclinical formulations: insight, strategies, and practical considerations.

Authors:  Sanket M Shah; Ankitkumar S Jain; Ritu Kaushik; Mangal S Nagarsenker; Maneesh J Nerurkar
Journal:  AAPS PharmSciTech       Date:  2014-06-12       Impact factor: 3.246

Review 8.  Engineering Cocrystals of PoorlyWater-Soluble Drugs to Enhance Dissolution in Aqueous Medium.

Authors:  Indumathi Sathisaran; Sameer Vishvanath Dalvi
Journal:  Pharmaceutics       Date:  2018-07-31       Impact factor: 6.321

Review 9.  In pursuit of functional electrospun materials for clinical applications in humans.

Authors:  Ryan J Stoddard; Arielle L Steger; Anna K Blakney; Kim A Woodrow
Journal:  Ther Deliv       Date:  2016-06-02

10.  Characterization of Solid Dispersion of Itraconazole Prepared by Solubilization in Concentrated Aqueous Solutions of Weak Organic Acids and Drying.

Authors:  Tapan Parikh; Harpreet K Sandhu; Tanaji T Talele; Abu T M Serajuddin
Journal:  Pharm Res       Date:  2016-03-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.